Scientific Reports
March 5, 2020
José Carlos Bouso, Daniel Jiménez‐garrido, María de Lourdes Gómez-sousa et al.
111 citations
Abstract Ayahuasca is a hallucinogenic decoction used as a traditional medicine in several Amazonian regions. The ritualistic use of ayahuasca has spread throughout many countries, making it necessary to study its risks and benefits. Two sub-studies were designed for this investigation. In sub-study 1, a psychiatric interview and a battery of questionnaires were administered to subjects (n =...
ACS Medicinal Chemistry Letters
March 2, 2020
Robert B. Kargbo
48 citations
Psilocybin, an active component in "magic mushroom", may have the potential to meet the therapeutic needs for a number of indications without the addictiveness and overdose risk of other mind-altering drugs, such as cocaine, heroin, alcohol, methamphetamine, and so forth. The need for new therapies is urgent because addiction, overdose, and suicide deaths have risen throughout the United States...
Journal of Attention Disorders
March 1, 2020
Molly Cairncross, Carlin J. Miller
Objective: Mindfulness-based therapies (MBTs) have been shown to be efficacious in treating internally focused psychological disorders (e.g., depression); however, it is still unclear whether MBTs provide improved functioning and symptom relief for individuals with externalizing disorders, including ADHD. To clarify the literature on the effectiveness of MBTs in treating ADHD and to guide...
The Brown University Psychopharmacology Update
March 1, 2020
Elderly patients with treatment‐resistant depression did not see overall improvement in depression symptoms over 28 days with use of esketamine nasal spray plus an oral antidepressant, a placebo‐controlled Phase 3 study has found. A younger subgroup of the overall study sample, as well as patients with earlier onset of depression, showed some improvement with esketamine, the researchers...
Journal of Psychopharmacology
March 1, 2020
Paul Glue, Shona Neehoff, A. Sabadel et al.
97 citations
Background: We previously reported that ketamine has anxiolytic effects in patients with treatment-resistant generalized anxiety and social anxiety disorders. Aims: The purpose of this study was to replicate our earlier report about ketamine‘s anxiolytic activity, using a more robust study design. Methods: This was a double-blind, psychoactive-controlled ascending dose study in 12 patients with...
March 1, 2020
Adam Winstock, James W. Rucker
29 citations
Abstract Psychedelics and hallucinogens represent some of the most commonly used drugs in the world, with a history of use steeped in spirituality, counter-culture, and more recently latent therapeutic potential. Sharing a common mechanism of action at the 5-HT2a receptor, drugs such as lysergic acid diethylamide (LSD) and psilocybin, while they can rarely induce significant short-term...
Behavioral Sciences
February 27, 2020
Reginald Paul R. Centeno, Karina Therese G. Fernandez
Attending college is meaningful for many young adults. This period is marked by physical, emotional, and psychological changes that can have both positive and negative effects on college students. The last two decades have seen an alarming increase in the number of college students who suffer from mental health conditions, such as depression, suicide, anxiety, and alcohol abuse. It is...
Metabolic Brain Disease
February 27, 2020
Camila Schoueri Colaço, Stefany Sousa Alves, Luciana Marangni Nolli et al.
56 citations
Ayahuasca is a hallucinogenic beverage that affects the serotonergic system and have therapeutic potential for many diseases and disorders, including depression and drug addiction. The objectives of this study were to evaluate the potential toxic effects of ayahuasca on rats after chronic exposure, and the levels of monoamines, their metabolites and the brain-derived neurotrophic factor (BDNF)...
Chemistry - A European Journal
February 26, 2020
Janis Fricke, Robert B. Kargbo, Lars Regestein et al.
48 citations
Abstract Psilocybin, the principal indole alkaloid of Psilocybe mushrooms, is currently undergoing clinical trials as a medication against treatment‐resistant depression and major depressive disorder. The psilocybin supply for pharmaceutical purposes is met by synthetic chemistry. We replaced the problematic phosphorylation step during synthesis with the mushroom kinase PsiK. This enzyme was...
BMJ Open
February 25, 2020
Maaike Maartje Rademaker, Inge Stegeman, Arno Lieftink et al.
Introduction: Chronic subjective tinnitus is a condition that affects 5.1% to 42.7% of the population, depending on the definition and studied population. Evidence-based treatment options are limited. Cognitive Behavioural Therapy (CBT) has been proven effective to improve quality of life and to diminish tinnitus distress. Positive short-term effects of mindfulness-based interventions on...